Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4292/wjgpt.v7.i2.190 http://scihub22266oqcxt.onion/10.4292/wjgpt.v7.i2.190 C4848241!4848241!27158534     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       World+J+Gastrointest+Pharmacol+Ther 2016 ; 7 (2): 190-206 Nephropedia Template TP {{tp|p=27158534|t=2016. Barrett?s esophagus in 2016: From pathophysiology to treatment |pdf=|usr=}}{{27158534}} gab.com Text Barrett s esophagus in 2016: From pathophysiology to treatment JO: World J Gastrointest Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=27158534 #FOAvip Esophageal complications caused by gastroesophageal reflux disease (GERD) include reflux esophagitis and Barrett?s esophagus (BE). BE is a premalignant condition with an increased risk of developing esophageal adenocarcinoma (EAC). The carcinogenic sequence may progress through several steps, from normal esophageal mucosa through BE to EAC. A recent advent of functional esophageal testing (particularly multichannel intraluminal impedance and pH monitoring) has helped to improve our knowledge about GERD pathophysiology, including its complications. Those findings (when properly confirmed) might help to predict BE neoplastic progression. Over the last few decades, the incidence of EAC has continued to rise in Western populations. However, only a minority of BE patients develop EAC, opening the debate regarding the cost-effectiveness of current screening/surveillance strategies. Thus, major efforts in clinical and research practice are focused on new methods for optimal risk assessment that can stratify BE patients at low or high risk of developing EAC, which should improve the cost effectiveness of screening/surveillance programs and consequently significantly affect health-care costs. Furthermore, the area of BE therapeutic management is rapidly evolving. Endoscopic eradication therapies have been shown to be effective, and new therapeutic options for BE and EAC have emerged. The aim of the present review article is to highlight the status of screening/surveillance programs and the current progress of BE therapy. Moreover, we discuss the recent introduction of novel esophageal pathophysiological exams that have improved the knowledge of the mechanisms linking GERD to BE. Twit Text FOAVip Barrett s esophagus in 2016: From pathophysiology to treatment ????World J Gastrointest Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=27158534 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27158534 #FOAvip English Wikipedia <ref>{{Cite pmid|27158534}}</ref> Barrett?s esophagus in 2016: From pathophysiology to treatment #MMPMID27158534 Martinucci I; de Bortoli N; Russo S; Bertani L; Furnari M; Mokrowiecka A; Malecka-Panas E; Savarino V; Savarino E; Marchi S World J Gastrointest Pharmacol Ther 2016[May]; 7 (2): 190-206 PMID27158534show ga Esophageal complications caused by gastroesophageal reflux disease (GERD) include reflux esophagitis and Barrett?s esophagus (BE). BE is a premalignant condition with an increased risk of developing esophageal adenocarcinoma (EAC). The carcinogenic sequence may progress through several steps, from normal esophageal mucosa through BE to EAC. A recent advent of functional esophageal testing (particularly multichannel intraluminal impedance and pH monitoring) has helped to improve our knowledge about GERD pathophysiology, including its complications. Those findings (when properly confirmed) might help to predict BE neoplastic progression. Over the last few decades, the incidence of EAC has continued to rise in Western populations. However, only a minority of BE patients develop EAC, opening the debate regarding the cost-effectiveness of current screening/surveillance strategies. Thus, major efforts in clinical and research practice are focused on new methods for optimal risk assessment that can stratify BE patients at low or high risk of developing EAC, which should improve the cost effectiveness of screening/surveillance programs and consequently significantly affect health-care costs. Furthermore, the area of BE therapeutic management is rapidly evolving. Endoscopic eradication therapies have been shown to be effective, and new therapeutic options for BE and EAC have emerged. The aim of the present review article is to highlight the status of screening/surveillance programs and the current progress of BE therapy. Moreover, we discuss the recent introduction of novel esophageal pathophysiological exams that have improved the knowledge of the mechanisms linking GERD to BE. äBarrett?s esophagus in 2016: From pathophysiology to treatment (epmc).pdf DeepDyve Pubget Overpricing